Afficher la notice abrégée

dc.rights.licenseopenen_US
dc.contributor.authorGERMAIN, Dominique P
dc.contributor.authorLEVADE, Thierry
dc.contributor.authorHACHULLA, Eric
dc.contributor.authorKNEBELMANN, Bertrand
hal.structure.identifierLaboratoire Maladies Rares: Génétique et Métabolisme (Bordeaux) [U1211 INSERM/MRGM]
dc.contributor.authorLACOMBE, Didier
dc.contributor.authorSEGUIN, Vanessa Leguy
dc.contributor.authorNGUYEN, Karine
dc.contributor.authorNOEL, Esther
dc.contributor.authorRABES, Jean-Pierre
dc.date.accessioned2023-11-02T12:48:19Z
dc.date.available2023-11-02T12:48:19Z
dc.date.issued2022-04-01
dc.identifier.issn1399-0004en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/184576
dc.description.abstractEnFabry disease (FD) is an X-linked genetic disease due to pathogenic variants in GLA. The phenotype varies depending on the GLA variant, alpha-galactosidase residual activity, patient's age and gender and, for females, X chromosome inactivation. Over 1000 variants have been identified, many through screening protocols more susceptible to disclose non-pathogenic variants or variants of unknown significance (VUS). This, together with the non-specificity of some FD symptoms, challenges physicians attempting to interpret GLA variants. The traditional way to interpreting pathogenicity is based on a combined approach using allele frequencies, genomic databases, global and disease-specific clinical databases, and in silico tools proposed by the American College of Medical Genetics and Genomics. Here, a panel of FD specialists convened to study how expertise may compare with the traditional approach. Several GLA VUS, highly controversial in the literature (p.Ser126Gly, p.Ala143Thr, p.Asp313Tyr), were re-analyzed through reviews of patients' charts. The same was done for pathogenic GLA variants with some specificities. Our data suggest that input of geneticists and physicians with wide expertise in disease phenotypes, prevalence, inheritance, biomarkers, alleles frequencies, disease-specific databases, and literature greatly contribute to a more accurate interpretation of the pathogenicity of variants, bringing a significant additional value over the traditional approach.
dc.language.isoENen_US
dc.rightsAttribution 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/us/*
dc.subject.enFabry Disease
dc.subject.enFemale
dc.subject.enGene Frequency
dc.subject.enHumans
dc.subject.enMutation
dc.subject.enPhenotype
dc.subject.enalpha-Galactosidase
dc.title.enChallenging the traditional approach for interpreting genetic variants: Lessons from Fabry disease.
dc.title.alternativeClin Geneten_US
dc.typeArticle de revueen_US
dc.identifier.doi10.1111/cge.14102en_US
dc.subject.halSciences du Vivant [q-bio]/Génétiqueen_US
dc.identifier.pubmed34927718en_US
bordeaux.journalClinical Geneticsen_US
bordeaux.page390-402en_US
bordeaux.volume101en_US
bordeaux.hal.laboratoriesMaladies Rares : Génétique et Métabolisme (MRGM) - UMR 1211en_US
bordeaux.issue4en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionINSERMen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
bordeaux.import.sourcepubmed
hal.popularnonen_US
hal.audienceInternationaleen_US
hal.exportfalse
workflow.import.sourcepubmed
dc.rights.ccPas de Licence CCen_US
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Clinical%20Genetics&rft.date=2022-04-01&rft.volume=101&rft.issue=4&rft.spage=390-402&rft.epage=390-402&rft.eissn=1399-0004&rft.issn=1399-0004&rft.au=GERMAIN,%20Dominique%20P&LEVADE,%20Thierry&HACHULLA,%20Eric&KNEBELMANN,%20Bertrand&LACOMBE,%20Didier&rft.genre=article


Fichier(s) constituant ce document

Thumbnail
Thumbnail

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée